Fever after intravitreal anti-VEGF injections.
Ladas
Ioannis D
ID
Kotsolis
Athanasios I
AI
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D005334:Fever / Q000139:chemically induced*; D006801:Humans; D056965:Injections, Intraocular; D008268:Macular Degeneration / Q000188:drug therapy*; D008297:Male; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab
Invest Ophthalmol Vis Sci. 2005 Feb;46(2):726-33
15671306
Ophthalmology. 2007 May;114(5):855-9
17467524